What the past year revealed and what leaders should expect next
Innovation in Life Sciences is never abstract. It shapes how long we live, how well we live, and how safely we move through the world. In 2025, that responsibility became impossible to ignore. What we witnessed was not merely a year of regulatory updates or revised annexes, but a profound acceleration of progress and one that underscored how deeply innovation and regulation are intertwined in building a healthier and safer future for global communities.
The fast pace of change in Life Sciences has pushed regulators into a new role. No longer focused only on oversight, they are now actively helping shape how innovation moves from the lab into the real world. By guiding how breakthroughs are tested, approved, and maintained, they strengthen trust and ensure that scientific progress delivers real value for patients and communities. This shift marked an important moment that underscored the importance of thoughtful, well-executed innovation for the future of Life Sciences.
It is energizing to see our PQE Group team serve as both a steady partner and an engaged contributor to these conversations and evolutions. Although regulatory complexity is intensifying, the true challenge I observed was not awareness. Most leaders understand what has changed. The real work lies in integration and embedding regulatory expectations into everyday operations, decision-making, and organizational culture so that innovation can scale responsibly and endure.
To see where compliance is headed, it helps to look back. Here is some insight from our team’s top regulatory moments and trends from 2025 and why they will shape 2026.
From Pilots to Regulated Reality
In 2025, we saw AI in GxP move from pilots into regulated reality. Updates to Annex 11 and the introduction of Annex 22 made it clear that explainability, continuous validation, and data integrity are now inspection priorities. Concerning this year, this shift creates opportunities as regulators focus less on written policies and more on how AI is governed in practice. Organizations that invest in living, adaptable governance models will be better positioned to manage risk, build trust, and scale AI responsibly, turning compliance into a foundation for confidence and sustainable innovation.
Check out our on-demand webinar: Navigating Safely Annex 11 and Annex 22 EU GMP Regulatory Changes. (Part 2 coming soon!)
Execution Takes Center Stage
The revised Annex 1 reinforced one of the defining themes of 2025: execution matters. Sterile manufacturing requirements shifted firmly from interpretation to enforcement, with regulators no longer satisfied by static contamination control strategies and instead expecting evidence of performance, continuous improvement, and meaningful reductions in human intervention. That same emphasis on real-world execution is now carrying forward, with inspections increasingly focused on how technologies such as AI are controlled in practice, not just documented. To meet these expectations, companies must embed mature, operational AI governance directly into their quality systems.
Check out our on-demand webinar: Annex 1: How to Stay Ahead in Sterile Manufacturing.
Proof Over Paper
The EMA’s updated benefit–risk framework, now extended to veterinary medicine, has reinforced a broader regulatory shift toward lifecycle accountability, environmental consideration, and sustained post-market oversight. In parallel, the expansion of decentralized trials, real-world evidence, and adaptive study designs has brought a sharper focus to data integrity and cross-border alignment. In 2026, this emphasis on execution is no longer emerging because it is already established. Regulators now expect contamination control strategies to be actively implemented, continuously improved, and supported by real performance data, not static risk assessments.
Check out our article: EMA’s 2025 Benefit-Risk Guidelines: Impact on Veterinary Medicine
Earlier Engagement, Smarter Pathways
One of the most positive signals from 2025 was the EMA’s push toward earlier, more structured engagement with sponsors. Through its eSubmission transformation, including updates to the electronic Technical Document, the agency has been encouraging earlier conversations, helping teams surface questions early and avoid avoidable delays later in the process. As this work persists, it is becoming clear that organizations willing to adapt their submission approaches and engage proactively are better positioned for smoother reviews and more predictable timelines. At its core, this shift reflects a shared commitment across the regulatory community to strengthen collaboration and support timely patient access.
Read more here: eSubmission EMA, EMA
Evidence-Based Regulation
In late 2025, the U.S. FDA issued draft guidance that removed the requirement for mandatory switching studies to achieve interchangeable biosimilar status, placing greater emphasis on analytical and pharmacokinetic evidence. As this approach takes hold this year, it signals a broader shift toward science-driven, pragmatic regulation by reducing development burden while supporting earlier patient access. This change may also influence regulatory thinking beyond the U.S., shaping global biosimilar strategies going forward.
Read more here: FDA, Arnold & Porter
Strengthening AI Governance
The White House AI Action Plan formally positioned the FDA as a key partner in regulatory sandboxes, enabling controlled experimentation with AI across drug discovery, clinical development, and manufacturing automation. As we settle into 2026, this work is helping drive closer alignment between U.S. and EU risk-based AI expectations, with greater emphasis on lifecycle monitoring, human oversight, and practical, operational governance. This emerging alignment encourages organizations to build adaptable, evidence-based AI controls that work across regions, reinforcing both innovation and public trust.
Read more here: PubMed
Predictable Development Pathways
The EMA began testing a more coordinated way for countries to review medical device and IVD trials together last year, rather than repeating the same assessments across borders. The goal was to reduce unnecessary duplication and help safe, effective technologies reach patients sooner. As this approach continues, it has the potential to make the development process clearer and more predictable for companies, while also supporting faster access to diagnostics and devices for healthcare systems and patients across Europe. At its best, this model reflects a shared effort to use regulatory resources more wisely and keep patient needs at the center of the process.
Read more here: European Commission pilot
The year ahead, like every other, invites us to be the change shaping the future of Life Sciences and our world. By moving from reaction to readiness and investing in governance, data-driven frameworks, and true cross-functional collaboration, organizations can turn complexity into confidence and progress into lasting impact for people everywhere. I am deeply proud to work alongside some of the best people in the world and to help build PQE Group into a truly global culture defined by expertise, integrity, and purpose. Success will belong to those who treat regulation not as a constraint, but as a strategic capability that protects communities, enables innovation, and builds enduring trust. Progress is not about moving faster alone; it’s about moving forward responsibly, together.
Stay tuned for upcoming webinars covering FDA Medical Device QMSR updates, a deep dive into Annex 22 and what it means for your business, EVDAS 2026 changes, and key pharmacovigilance updates across both human and veterinary medicine.
